Guidelines for prevention of Pneumocystis carinii pneumonitis in children and adolescents with cancer;Empfehlungen zur prävention der Pneumocystis-carinii-pneumonie bei kindern und jugendlichen mit neoplastischen erkrankungen

Klinische Padiatrie

Volumn 213, Issue SUPPL. 1, 2001, Pages

  Groll, A H ^a   Ritter, J ^b   Muller F M C ^c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Atovaquone; Cancer; Children; Dapsone; Mycoses; Pentamidine; Pneumocystis carinii; Recommendations; Trimethoprim sulfamethoxazole

Indexed keywords

ATOVAQUONE; COTRIMOXAZOLE; DAPSONE; PENTAMIDINE; PLACEBO;

ADOLESCENT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BLOOD DISEASE; CANCER PATIENT; CHEMOPROPHYLAXIS; CHILD; EVIDENCE BASED MEDICINE; HEMATOLOGIC DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK POPULATION; HUMAN; OPPORTUNISTIC INFECTION; PNEUMOCYSTIS PNEUMONIA; PRACTICE GUIDELINE; SOLID TUMOR; T LYMPHOCYTE ACTIVATION;

EID: 0034829201     PISSN: 03008630     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2001-17501     Document Type: Article

References (116)

1. Antibiotic drug allergy in children
2. Aerosolized pentamidine, cotrimoxazole and dapsone-pyrimethamine for primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis
3. Activity of antifols against Pneumocystis carinii dihydrofolate reductase and identification of a potent new agent
4. Clindamycin/primaquine as prophylaxis for Pneumocystis carinii pneumonia
5. Lymphocytes in host defense against Pneumocystis carinii
6. Possible transfer of Pneumocystis carinii between kidney transplant recipients
7. A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection
8. Pneumocystis pneumonia transmission between patients with lymphoma
9. Excess prevalence of Pneumocystis carinii pneumonia in patients treated for lymphoma with combination chemotherapy
10. Opportunistic pulmonary infections with fludarabine in previously treated patients with low-grade lymphoid malignancies: A role for Pneumocystis carinii pneumonia prophylaxis
11. Low-dose trimethoprim-sulfamethoxazole prophylaxis for toxoplasmic encephalitis in patients with AIDS
12. Guidelines for prophylaxis against Pneumocystis carinii pneumonia for persons infected with human immunodeficiency virus
13. 1995 revised guidelines for prophylaxis against Pneumocystis carinii pneumonia for children infected with or perinatally exposed to human immunodeficiency virus
14. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients
15. Atovaquone suspension compared with aerosolized pentamidine for prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected subjects intolerant of trimethoprim or sulfonamides
16. Life-threatening reaction to trimethoprim/sulfamethoxazole in pediatric human immunodeficiency virus infection
17. Transmission of Pneumocystis carinii from AIDS patients to other immunosuppressed patients: A cluster of Pneumocystis carinii pneumonia in renal transplant recipients
18. A prospective randomized trial comparing the toxicity and safety of atovaquone with trimethoprim/sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis following autologous peripheral blood stem cell transplantation
19. Concentrations of aerosolized pentamidine in bronchoalveolar lavage, systemic absorption, and excretion
20. Pneumocystis carinii infection in children with acute leukemia and non-Hodgkin malignant lymphoma
21. Animal models of pneumocystosis
22. Pneumocystis pneumonia in patients with cancer: Clinical setting
23. Atypical presentations of Pneumocystis carinii pneumonia in patients receiving inhaled pentamidine prophylaxis
24. Ribosomal RNA sequence shows Pneumocystis carinii to be a member of the fungi
25. Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both
26. Once-a-month administration of intravenous pentamidine to patients infected with human immunodeficiency virus as prophylaxis for Pneumocystis carinii pneumonia
27. Interaction between trimethoprim-sulfamethoxazole and methotrexate in children with leukemia
28. Fansidar prophylaxis of Pneumocystis pneumonia in the acquired immunodeficiency syndrome
29. Prevention of infection due to Pneumocystis carinii
30. Guideline for isolation precautions in hospitals
31. Dapsone-pyrimethamine compared with aerosolized pentamidine as primary prophylaxis against Pneumocystis carinii pneumonia and toxoplasmosis in HIV infection
32. Rapid oral desensitization to trimethoprim-sulfamethoxazole (TMP-SMZ): Use in prophylaxis for Pneumocystis carinii pneumonia in patients with AIDS who were previously intolerant to TMP-SMZ
33. Possible transfer of Pneumocystis carinii between immunodeficient patients
34. Pneumocystis-carinii Pneumonie unter inhalativer Pentamidin-prophylaxe
35. AIDS-associated atypical Pneumocystis carinii pneumonia revisited
36. Fortschritte in prävention und therapie infektiöser komplikationen bei kindern und jugendlichen mit neoplastischen erkrankungen
37. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome
38. A controlled study of inhaled pentamidine for primary prevention of Pneumocystis carinii pneumonia
39. Phase I safety and pharmacokinetics study of micronized atovaquone in human immunodeficiency virus-infected infants and children
40. Intensity of immunosuppressive therapy and the incidence of Pneumocystis carinii pneumonitis
41. Successful chemoprophylaxis for Pneumocystis carinii pneumonitis
42. Pneumocystis carinii pneumonitis in children with malignancies
43. Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis
44. Current issues in the epidemiology, transmission, and reactivation of Pneumocystis carinii
45. Pneumocystis carinii pneumonia: New approaches to diagnosis, treatment and prevention
46. Use of dapsone in the prevention and treatment of Pneumocystis carinii pneumonia: A review
47. A meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens
48. Trimethoprim-sulfamethoxazole anaphylactoid reactions in patients with AIDS: Case reports and literature review
49. Aerosolized pentamidine: Effect on diagnosis and presentation of Pneumocystis carinii pneumonia
50. Mechanisms of drug interactions
51. Clindamycin/primaquine therapy and secondary prophylaxis against Pneumocystis carinii pneumonia in patients with AIDS
52. Pneumocystis carinii mutations associated with sulfa and sulfone prophylaxis failures in AIDS patients
53. Pneumocystis carinii pneumonia: A comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies
54. First experience with pentamidine inhalation in human immunodeficiency virus-infected children
55. The scid mouse as an experimental model for the evaluation of anti-Pneumocystis carinii therapy
56. Therapy-induced alterations in host defense in children receiving therapy for cancer
57. Aerosolized pentamidine for prophylaxis against Pneumocystis carinii pneumonia. The San Francisco community prophylaxis trial
58. The role of alveolar macrophages in Pneumocystis carinii degradation and clearance from the lung
59. Pentamidine aerosol for prophylaxis of Pneumocystis carinii pneumonia after BMT
60. Late onset Pneumocystis carinii pneumonia following allogeneic bone marrow transplantation
61. Pneumocystis carinii dihydropteroate synthase but not dihydrofolate reductase gene mutations correlate with prior trimethoprim-sulfamethoxazole or dapsone use
62. Expression and characterization of recombinant human-derived Pneumocystis carinii dihydrofolate reductase
63. Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy
64. Lymphocyte depletion during treatment with intensive chemotherapy for cancer
65. Prolonged CD4 depletion after sequential autologous peripheral blood progenitor cell infusions in children and young adults
66. T-cell immunodeficiency following cytotoxic anti-neoplastic therapy: A review
67. Dapsone for Pneumocystis carinii prophylaxis in children undergoing bone marrow transplantation
68. Antimicrobial Agents: Sulfonamides, Trimethoprim-Sulfamethoxazole, Quinolones and agents for urinary tract infections
69. Desensitization to trimethoprim-sulfamethoxazole following lung transplantation
70. CD4 counts as predictors of opportunistic pneumonias in human immunodeficiency virus (HIV) infection
71. Pneumocystis carinii Pneumonia
72. Toxicity and efficacy of daily vs. weekly dapsone for prevention of Pneumocystis carinii pneumonia in children infected with human immunodeficiency virus
73. Failure of co-trimoxazole in Pneumocystis carinii infection and mutations in dihydropteroate synthase gene
74. Desensitization to dapsone in HIV-positive patients
75. The value of Pneumocystis carinii antibody and antigen detection for diagnosis of Pneumocystis carinii pneumonia after marrow transplantation
76. Pharmacokinetics of dapsone administered daily and weekly in human immunodeficiency virus-infected children
77. Current approaches to diagnosis and treatment of fungal infections in HIV-infected children
78. Aerosolized pentamidine for the prevention of Pneumocystis carinii pneumonia in children with cancer intolerant or allergic to trimethoprim/sulfamethoxazole
79. High failure rate of dapsone and pentamidine as Pneumocystis carinii pneumonia prophylaxis in human immunodeficiency virus-infected children
80. Extrapulmonary pneumocystosis
81. Pneumocystis-carinii-Pneumonie
82. Once-weekly administration of dapsone/pyrimethamine vs. aerosolized pentamidine as combined prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus-infected patients
83. Aerosolized pentamidine: A well-tolerated mode of prophylaxis against Pneumocystis carinii pneumonia in older children with human immunodeficiency virus infection
84. Reduced toxicity with gradual initiation of trimethoprim-sulfamethoxazole as primary prophylaxis for Pneumocystis carinii pneumonia: AIDS Clinical Trials Group 268
85. Pneumocystis carinii infection: Evidence for high prevalence in normal and immunosuppressed children
86. Intermittent trimethoprim-sulfamethoxazole compared with dapsone-pyrimethamine for the simultaneous primary prophylaxis of Pneumocystis pneumonia and toxoplasmosis in patients infected with HIV
87. Thrice-weekly cotrimoxazole is better than weekly dapsone-pyrimethamine for the primary prevention of Pneumocystis carinii pneumonia in HIV-infected patients
88. Pneumocystis carinii interactions with respiratory epithelium
89. Disturbance of 6-mercaptopurine metabolism by cotrimoxazole in childhood lymphoblastic leukaemia
90. Infections in bone marrow transplant recipients
91. Adjunctive folinic acid with trimethoprim-sulfamethoxazole for Pneumocystis carinii pneumonia in AIDS patients is associated with an increased risk of therapeutic failure and death
92. A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection
93. Effect of prophylaxis on the clinical manifestations of AIDS-related opportunistic infections
94. Pneumocystis carinii pneumonia in patients without AIDS
95. Pulmonary infiltrates and hypoxemia in patients with the acquired immunodeficiency syndrome re-exposed to trimethoprim-sulfamethoxazole
96. Preventing Pneumocystis carinii pneumonia in persons infected with human immunodeficiency virus
97. Fatalities during remission of childhood leukemia
98. Pneumocystis carinii pneumonia during steroid taper in patients with primary brain tumors
99. High rates of Pneumocystis carinii pneumonia in allogeneic blood and marrow transplant recipients receiving dapsone prophylaxis
100. Atovaquone. A review of its pharmacological properties and therapeutic efficacy in opportunistic infections
101. Randomized trial of dapsone and aerosolized pentamidine for the prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis
102. Drugs used in the chemotherapy of protozoal infections
103. AIDS/HIV. Drugs for opportunistic infections
104. Pneumocystis carinii pneumonitis following bone marrow transplantation
105. 1997 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: Disease-specific recommendations
106. 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus
107. Effects of aerosolized pentamidine on glucose homeostasis and insulin secretion in HIV-positive patients: A controlled study
108. Aerosolized pentamidine as pneumocystis prophylaxis after bone marrow transplantation is inferior to other regimens and is associated with decreased survival and an increased risk of other infections
109. Trimethoprim-sulfamethoxazole salvage for refractory listeriosis during maintenance chemotherapy for acute lymphoblastic leukemia
110. Sequence polymorphisms in the Pneumocystis carinii cytochrome b gene and their association with atovaquone prophylaxis failure
111. Pneumocystis carinii pneumonia in patients without human immunodeficiency virus infection
112. Pneumocystis carinii
113. Activities of antifolate, antiviral, and other drugs in an immunosuppressed rat model of Pneumocystis carinii pneumonia
114. Successful Pneumocystis carinii pneumonia prophylaxis using aerosolized pentamidine in children with acute leukemia
115. Clinical pharmacokinetics of dapsone